LakeShore Biopharma Co., Ltd Cash Flow-to-Debt Ratio
LakeShore Biopharma Co., Ltd cash flow-to-debt ratio. LakeShore Biopharma Co., Ltd (LSBCF) has a Cash Flow-to-Debt Ratio of -0.01x as of June 2022, meaning its operating cash flow of $-693.96K could theoretically repay 0% of its total liabilities ($76.38 Million) in one year. Check LakeShore Biopharma Co., Ltd (LSBCF) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of LakeShore Biopharma Co., Ltd (2021–2025)
Cash flow-to-debt ratio of LakeShore Biopharma Co., Ltd from 2021 to 2025. Historical debt coverage capacity for LakeShore Biopharma Co., Ltd across 5 annual periods. Check LakeShore Biopharma Co., Ltd (LSBCF) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
LakeShore Biopharma Co., Ltd Cash Flow-to-Debt Ratio by Year (2021–2025)
LakeShore Biopharma Co., Ltd cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for LakeShore Biopharma Co., Ltd. For the full cash flow conversion analysis, see LSBCF cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.14x | $-120.98 Million | $867.91 Million | ▲ +56.2% |
| 2024 | -0.32x | $-295.23 Million | $927.82 Million | ▼ -72.9% |
| 2023 | -0.18x | $-182.47 Million | $991.30 Million | ▲ +97.8% |
| 2022 | -8.53x | $-173.55 Million | $20.35 Million | ▲ +99.8% |
| 2021 | -3522.50x | $-246.61 Million | $70.01K | — |